New product: Evrysdi (risdiplam) 0.75 mg/mL powder for oral solution

Risdiplam is licensed for the treatment of 5q spinal muscular atrophy (SMA) in patients 2 months of age and older, with a clinical diagnosis of SMA Type 1, Type 2 or Type 3 or with one to four SMN2 copies.

Source:

electronic Medicines compendium